相关实验视频

Updated: Jun 14, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

毛囊和细胞甲状腺癌中的分子标记物:分子遗传检测的临床应用

Alicia Belaiche¹, Grégoire B Morand^2,3,4, Sena Turkdogan^2,5

¹Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada.

Current oncology (Toronto, Ont.)

|October 25, 2024

概括

瘤细胞性甲状腺癌 (OTC) 和卵泡性甲状腺癌 (FTC) 是不同的. 分子检测和细胞学可以帮助在手术前区分这些甲状腺癌,帮助诊断和治疗.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
分子病理学分子病理学

背景情况:

瘤细胞性甲状腺癌 (OTC) 最近被重新分类为与卵泡性甲状腺癌 (FTC) 不同的实体.
在手术前区分FTC和OTC是具有挑战性的,但对于患者管理至关重要.

研究的目的:

为了证明FTC和OTC是从根本上不同的实体.
评估手术前细胞学和分子测试在区分FTC和OTC方面的潜力.

主要方法:

在2016年1月至2023年9月期间被诊断患有FTC或OTC的3219名患者的回顾性图表审查.
在50名符合条件的患者中,分子检测结果与组织病理学诊断的相关性.
对临床病理特征的分析,包括年龄,瘤的攻击性和细胞学发现.

主要成果:

与FTC患者相比,OTC患者年龄较大,具有更高的侵袭性瘤发病率.
在贝塞斯达类别III和IV中,细胞检测显示在OTC (85.0%) 中瘤细胞亚型比FTC (20.8%) 更频繁.
观察到明显的分子变化:OTC中的EIF1AX,FTC中的PAX8/PPARy和PTEN. 在OTC中,拷贝数变化 (CNA) 和多个分子变化的流行率更高.

结论:

这项研究证实了OTC与FTC相比具有明显的临床病理和分子特征.
细胞学和分子检测显示出OTC和FTC的术前分化有前途,支持将它们重新分类为独立实体.

关键词:

赫尔特尔细胞癌 (Hürthle cell carcinoma) 是一种癌症.囊性甲状腺癌 (Thyroid carcinoma) 是一种癌症.分子测试试验分子测试瘤细胞甲状腺癌瘤.甲状腺癌是一种癌症.

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...